

Supplemental Table 1 - Direction and degree of change for all samples as in Barone et al. Figure 6*

Sample ID	Disease at day 0	Sample source	Population analyzed	Total cells	Studied intervention	Outcome	Day compared	# cells, [0,5]	# cells, [5,15]	# cells, [15,85]	# cells, [85,95]	# cells, [95,100]	# cells, total	Change magnitude	Change direction
RV001	Healthy	PBMC	CD4+ T cells	1.37E+06	Rhinovirus challenge	infected	7	9	885	1363363	2080	1155	1367492	0.09%	0.985
RV002	Healthy	PBMC	CD4+ T cells	2.48E+06	Rhinovirus challenge	uninfected	7	9	329	2480954	0	0	2481292	0.00%	-1.000
RV003	Healthy	PBMC	CD4+ T cells	2.62E+06	Rhinovirus challenge	uninfected	7	0	271	2613703	3615	1667	2619256	0.06%	1.000
RV004	Healthy	PBMC	CD4+ T cells	3.25E+06	Rhinovirus challenge	infected	7	291	4103	3243461	1316	11	3249182	0.01%	-0.927
RV005	Healthy	PBMC	CD4+ T cells	2.30E+06	Rhinovirus challenge	infected	7	14	879	2303653	46	0	2304592	0.00%	-1.000
RV006	Healthy	PBMC	CD4+ T cells	1.53E+06	Rhinovirus challenge	infected	7	0	280	1528931	1302	139	1530652	0.01%	1.000
RV007	Healthy	PBMC	CD4+ T cells	1.48E+06	Rhinovirus challenge	infected	7	6168	6858	1467017	95	0	1480138	0.42%	-1.000
RV008	Healthy	PBMC	CD4+ T cells	1.16E+06	Rhinovirus challenge	infected	7	0	71	1154970	622	341	1156004	0.03%	1.000
COV24	COVID-19	PBMC	All cells	6.34E+04	N/A	ICU	3	3	1105	58091	3580	647	63426	1.025%	0.991
COV26	COVID-19	PBMC	All cells	1.19E+05	N/A	ICU	6	4	338	111308	5389	2409	119448	2.020%	0.997
COV27	COVID-19	PBMC	All cells	4.90E+04	N/A	ICU	1	12	1859	45592	1532	11	49006	0.047%	-0.043
COV29	COVID-19	PBMC	All cells	1.64E+05	N/A	ICU	4	12208	17659	113306	17287	3920	164380	9.811%	-0.514
COV32	COVID-19	PBMC	All cells	3.21E+05	N/A	non ICU	6	119305	18635	51651	31496	99643	320730	68.266%	-0.090
COV34	COVID-19	PBMC	All cells	4.97E+05	N/A	ICU	7	97380	70135	164237	99849	64921	496522	32.688%	-0.200
COV35	COVID-19	PBMC	All cells	8.14E+04	N/A	ICU	4	141	3044	74262	3341	610	81398	0.923%	0.625
COV36	COVID-19	PBMC	All cells	2.96E+05	N/A	non ICU	5	5494	5497	271632	7703	6112	296438	3.915%	0.053
COV37	COVID-19	PBMC	All cells	5.81E+03	N/A	ICU	5	1839	523	977	538	1937	5814	64.947%	0.026
COV39	COVID-19	PBMC	All cells	1.94E+05	N/A	ICU	4	45209	12696	88567	30561	16717	193750	31.962%	-0.460
COV40	COVID-19	PBMC	All cells	4.84E+04	N/A	ICU	6	347	1477	42432	3151	959	48366	2.700%	0.469
COV41	COVID-19	PBMC	All cells	9.82E+04	N/A	ICU	4	15488	9468	62216	8458	2598	98228	18.412%	-0.713
MB004	Melanoma	PBMC	All cells	1.69E+05	α-PD immunotherapy	complete	3	4975	20025	115912	22236	5672	168820	6.307%	0.065
MB005	Melanoma	PBMC	All cells	1.54E+05	α-PD immunotherapy	complete	3	1117	1636	149069	2042	60	153924	0.765%	-0.898
MB006	Melanoma	PBMC	All cells	1.92E+05	α-PD immunotherapy	progressive	5	11418	4735	172333	3476	276	192238	6.083%	-0.953
MB007	Melanoma	PBMC	All cells	1.72E+05	α-PD immunotherapy	progressive	3	536	2916	168874	154	0	172480	0.311%	-1.000
MB008	Melanoma	PBMC	All cells	2.33E+05	α-PD immunotherapy	partial	3	5991	7137	211481	8094	491	233194	2.780%	-0.849
MB009	Melanoma	PBMC	All cells	4.65E+05	α-PD immunotherapy	stable	3	1838	6903	455082	1401	0	465224	0.395%	-1.000
MB010	Melanoma	PBMC	All cells	3.94E+05	α-PD immunotherapy	partial	3	0	478	392391	851	20	393740	0.005%	1.000
MB012	Melanoma	PBMC	All cells	1.65E+05	α-PD immunotherapy	partial	3	459	6870	147120	7973	2306	164728	1.679%	0.668
MB013	Melanoma	PBMC	All cells	4.29E+05	α-PD immunotherapy	partial	6	56	579	424404	3654	449	429142	0.118%	0.778
MB041	Melanoma	PBMC	All cells	3.45E+05	α-PD immunotherapy	progressive	3	0	0	344611	13	0	344624	0.000%	0.000
AML001	AML	PBMC	All cells	6.31E+04	Chemotherapy	CR	5	31498	7	131	161	31341	63138	99.526%	-0.002
AML002	AML	PBMC	All cells	7.40E+04	Chemotherapy	CR	8	29663	5074	5134	3878	30209	73958	80.954%	0.009
AML003	AML	PBMC	All cells	6.83E+05	Chemotherapy	PD	5	1667	48603	556652	55640	20082	682644	3.186%	0.847
AML004	AML	PBMC	All cells	3.41E+05	Chemotherapy	CR	8	139293	21982	25628	16694	137025	340622	81.122%	-0.008
AML007	AML	PBMC	All cells	1.94E+05	Chemotherapy	CR	8	6203	14309	144865	22967	5370	193714	5.974%	-0.072

*For studied interventions and outcomes, see original manuscripts for detailed information. Day compared indicates the actual day a sample was taken relative to a day 0 comparison in all cases. #cells indicates the number of cells in each percentile grouping (e.g. [0,5] indicates the number of cells whose KNN area had less than or equal to 5% change in T-REX analysis). Change magnitude and direction are as in Figure 6A.